A6 Peptide Activates CD44 Adhesive Activity, Induces FAK and MEK Phosphorylation, and Inhibits the Migration and Metastasis of CD44-Expressing Cells
- 1 November 2011
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 10 (11) , 2072-2082
Abstract
The A6 peptide (acetyl-KPSSPPEE-amino) has antitumor activity in the absence of significant adverse events in murine tumor models and clinical trials. A6 shares sequence homology with CD44, an adhesion receptor involved in metastasis that is also a marker of cancer stem cells and drug-resistant phenotypes. We investigated the mechanism of action of A6 by examining its effects on CD44 activity, cell migration, and metastasis. A6 inhibited the migration of a subset of ovarian and breast cancer cell lines, exhibiting IC50 values of 5 to 110 nmol/L. The ability of A6 to inhibit migration in vitro correlated with CD44 expression. Immunopreciptation studies showed that CD44 binds A6 and that biotin-tagged A6 can be cross-linked to CD44. The binding of A6 altered the structure of CD44 such that it was no longer recognized by a monoclonal antibody to a specific epitope. Importantly, A6 potentiated the CD44-dependent adhesion of cancer cells to hyaluronic acid and activated CD44-mediated signaling, as evidenced by focal adhesion kinase and MAP/ERK kinase phosphorylation. In vivo, A6 (100 mg/kg delivered s.c. twice daily) reduced the number of lung foci generated by the i.v. injection of B16-F10 melanoma cells by 50% (P = 0.029 in an unpaired t test). We conclude that A6 potently blocks the migration of CD44-positive cells in vitro through an interaction with CD44 that alters its structure and activates CD44 to enhance ligand binding and downstream signaling. The concurrent ability of A6 to agonize the CD44 receptor suggests that CD44 activation may represent a novel strategy for inhibiting metastatic disease. Mol Cancer Ther; 10(11); 2072–82. ©2011 AACR.Keywords
This publication has 31 references indexed in Scilit:
- Cellular functions of FAK kinases: insight into molecular mechanisms and novel functionsJournal of Cell Science, 2010
- A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous Å6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancerGynecologic Oncology, 2008
- Hyaluronan: A constitutive regulator of chemoresistance and malignancy in cancer cellsSeminars in Cancer Biology, 2008
- Å6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: A phase I trialGynecologic Oncology, 2005
- CD44 Interaction with c-Src Kinase Promotes Cortactin-mediated Cytoskeleton Function and Hyaluronic Acid-dependent Ovarian Tumor Cell MigrationJournal of Biological Chemistry, 2001
- Identification of Two Regions in the Cytoplasmic Domain of CD44 through Which PMA, Calcium, and Foskolin Differentially Regulate the Binding of CD44 to Hyaluronic AcidCellular Immunology, 1998
- Variant cell lines selected for alterations in the function of the hyaluronan receptor CD44 show differences in glycosylation.Journal of Experimental Medicine, 1995
- Antibody‐induced activation of the hyaluronan receptor function of CD44 requires multivalent binding by antibodyEuropean Journal of Immunology, 1993
- Lymphocyte CD44 binds the COOH-terminal heparin-binding domain of fibronectin.Journal of Cell Biology, 1992
- Amelioration of B16F10 melanoma lung metastasis in mice by a combination therapy with indomethacin and interleukin 2.Journal of Experimental Medicine, 1987